Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.

被引：7
|
作者：
Kelly, Ronan Joseph
Lee, Jeeyun
Bang, Yung-Jue
Almhanna, Khaldoun
Murphy, Mariela A. Blum
Catenacci, Daniel V. T.
Chung, Hyun Cheol
Wainberg, Zev A.
Gibson, Michael
Lee, Keun Wook
Bendell, Johanna C.
Denlinger, Crystal S.
Brohawn, Philip Z.
He, Peng
McDevitt, Jennifer
Englert, Judson
Ku, Geoffrey Yuyat
机构：
[1] Johns Hopkins Med, Baltimore, MD USA
[2] Samsung Med Ctr, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Chicago, Med Comprehens Canc Ctr, Chicago, IL 60637 USA
[7] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[9] Univ Hosp Case, Med Ctr, Cleveland, OH USA
[10] Seoul Natl Univ, Bundang Hosp, Seoul Natl Univ Coll Med, Seoul, South Korea
[11] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[12] Fox Chase Canc Ctr, Philadelphia, PA USA
[13] MedImmune, Gaithersburg, MD USA
[14] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4031
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase 3b safety study of fixed-dose durvalumab plus tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A.
    Sonpavde, Guru
    Peters, Solange
    Nordquist, Luke T.
    Kato, Terufumi
    Miranda, Paulo Andre
    Wang, Qin
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [42] Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer.
    Kundu, Palak
    Lee, Alan
    Drakaki, Alexandra
    Liu, Sandy
    Shen, John
    Chin, Arnold I.
    Chamie, Karim
    Chang, Albert
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [43] Safety and activity of second-line durvalumab plus tremelimumab in non-squamous advanced NSCLC
    Chaft, Jamie
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Le Moulec, Sylvestre
    Cho, Eun Kyung
    Papadimitrakopoulou, Vassiliki
    Garon, Edward
    Lee, Sylvia
    Aix, Santiago Ponce
    Ma, Patrick C.
    Otterson, Gregory
    Narwal, Rajesh
    Gao, Guozhi
    McDevitt, Jennifer
    Englert, Judson
    Antonia, Scott
    CANCER RESEARCH, 2018, 78 (13)
  • [44] Single-cell profiling of NSCLC tumor treated with Durvalumab and in combination with Tremelimumab
    Shrestha, Yashaswi
    Zhang, Qu
    Cheng, Li
    Halpin, Rebecca
    Higgs, Brandon W.
    Raja, Rajiv
    Streicher, Katie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Evaluation of the safety and the tolerability of durvalumab plus tremelimumab combined with FOLFOX in metastatic colorectal cancer (MEDITREME)
    Fumet, J-D.
    Isambert, N.
    Hervieu, A.
    Zanetta, S.
    Guion, J-F.
    Hennequin, A.
    Rederstorff, E.
    Bertaut, A.
    Ghiringhelli, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 31 - 31
  • [46] Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
    Ioka, Tatsuya
    Ueno, Makoto
    Oh, Do-Youn
    Fujiwara, Yutaka
    Chen, Jen-Shi
    Doki, Yuichiro
    Mizuno, Nobumasa
    Park, Keunchil
    Asagi, Akinori
    Hayama, Manabu
    Nii, Masahiro
    Komuro, Keiko
    Sugimoto, Mariko
    Vlahovic, Gordana
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [47] Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
    Goldman, Jonathan W.
    Piha-Paul, Sarina A.
    Curti, Brendan
    Pedersen, Katrina S.
    Bauer, Todd M.
    Groenland, Stefanie L.
    Carvajal, Richard D.
    Chhaya, Vaishali
    Kirby, Gray
    McGlinchey, Kelly
    Hammond, Scott A.
    Streicher, Katie
    Townsley, Danielle M.
    Chae, Young Kwang
    Voortman, Jens
    Marabelle, Aurelien
    Powderly, John
    CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3709 - 3719
  • [48] Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
    Capdevila, J.
    Hernando, J.
    Teule, A.
    Lopez, C.
    Garcia-Carbonero, R.
    Benavent, M.
    Custodio, A.
    Garcia-Alvarez, A.
    Cubillo, A.
    Alonso, V.
    Carmona-Bayonas, A.
    Alonso-Gordoa, T.
    Crespo, G.
    Jimenez-Fonseca, P.
    Blanco, M.
    Viudez, A.
    La Casta, A.
    Sevilla, I.
    Segura, A.
    Llanos, M.
    Landolfi, S.
    Nuciforo, P.
    Manzano, J. L.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [49] Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
    J. Capdevila
    J. Hernando
    A. Teule
    C. Lopez
    R. Garcia-Carbonero
    M. Benavent
    A. Custodio
    A. Garcia-Alvarez
    A. Cubillo
    V. Alonso
    A. Carmona-Bayonas
    T. Alonso-Gordoa
    G. Crespo
    P. Jimenez-Fonseca
    M. Blanco
    A. Viudez
    A. La Casta
    I. Sevilla
    A. Segura
    M. Llanos
    S. Landolfi
    P. Nuciforo
    J. L. Manzano
    Nature Communications, 14
  • [50] Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
    Sohal, Davendra
    Moreland, Katie
    Quillin, Ralph
    Lemon, Kristina
    Rojan, Adam
    Olowokure, Olugbenga Olanrele
    Shah, Shimul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS638 - TPS638
12345